CLINICAL TRIALS PROFILE FOR TRIAMCINOLONE ACETATE

All Clinical Trials for Triamcinolone Acetate

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00148265 ↗	A Multicentre Randomised Clinical Trial of Laser Treatment Plus Intravitreal Triamcinolone for Diabetic Macular Oedema	Completed	Marsden Eye Centre	Phase 2/Phase 3	2005-04-01	This study is likely to identify an improved and economical treatment for diabetic macular oedema, one of the commonest causes of blindness both in Australia and the rest of the world.The specific aims of the study are to test the following hypotheses: - That intravitreal triamcinolone followed by laser treatment results in a greater improvement in visual acuity than placebo followed by laser treatment of eyes with macular oedema secondary to diabetes; - That intravitreal triamcinolone followed by laser treatment results in greater degree of resolution of macular oedema than placebo followed by laser treatment of eyes with macular oedema secondary to diabetes; - That intravitreal triamcinolone followed by laser treatment results in a reduced requirement for further laser treatment to control diabetic macular oedema than placebo followed by laser treatment; - That intravitreal triamcinolone followed laser has a manageable and acceptable safety profile in eyes with diabetic macular edema.
NCT00148265 ↗	A Multicentre Randomised Clinical Trial of Laser Treatment Plus Intravitreal Triamcinolone for Diabetic Macular Oedema	Completed	Marsden Eye Specialists	Phase 2/Phase 3	2005-04-01	This study is likely to identify an improved and economical treatment for diabetic macular oedema, one of the commonest causes of blindness both in Australia and the rest of the world.The specific aims of the study are to test the following hypotheses: - That intravitreal triamcinolone followed by laser treatment results in a greater improvement in visual acuity than placebo followed by laser treatment of eyes with macular oedema secondary to diabetes; - That intravitreal triamcinolone followed by laser treatment results in greater degree of resolution of macular oedema than placebo followed by laser treatment of eyes with macular oedema secondary to diabetes; - That intravitreal triamcinolone followed by laser treatment results in a reduced requirement for further laser treatment to control diabetic macular oedema than placebo followed by laser treatment; - That intravitreal triamcinolone followed laser has a manageable and acceptable safety profile in eyes with diabetic macular edema.
NCT00148265 ↗	A Multicentre Randomised Clinical Trial of Laser Treatment Plus Intravitreal Triamcinolone for Diabetic Macular Oedema	Completed	The University of Western Australia	Phase 2/Phase 3	2005-04-01	This study is likely to identify an improved and economical treatment for diabetic macular oedema, one of the commonest causes of blindness both in Australia and the rest of the world.The specific aims of the study are to test the following hypotheses: - That intravitreal triamcinolone followed by laser treatment results in a greater improvement in visual acuity than placebo followed by laser treatment of eyes with macular oedema secondary to diabetes; - That intravitreal triamcinolone followed by laser treatment results in greater degree of resolution of macular oedema than placebo followed by laser treatment of eyes with macular oedema secondary to diabetes; - That intravitreal triamcinolone followed by laser treatment results in a reduced requirement for further laser treatment to control diabetic macular oedema than placebo followed by laser treatment; - That intravitreal triamcinolone followed laser has a manageable and acceptable safety profile in eyes with diabetic macular edema.
NCT00148265 ↗	A Multicentre Randomised Clinical Trial of Laser Treatment Plus Intravitreal Triamcinolone for Diabetic Macular Oedema	Completed	University of Melbourne	Phase 2/Phase 3	2005-04-01	This study is likely to identify an improved and economical treatment for diabetic macular oedema, one of the commonest causes of blindness both in Australia and the rest of the world.The specific aims of the study are to test the following hypotheses: - That intravitreal triamcinolone followed by laser treatment results in a greater improvement in visual acuity than placebo followed by laser treatment of eyes with macular oedema secondary to diabetes; - That intravitreal triamcinolone followed by laser treatment results in greater degree of resolution of macular oedema than placebo followed by laser treatment of eyes with macular oedema secondary to diabetes; - That intravitreal triamcinolone followed by laser treatment results in a reduced requirement for further laser treatment to control diabetic macular oedema than placebo followed by laser treatment; - That intravitreal triamcinolone followed laser has a manageable and acceptable safety profile in eyes with diabetic macular edema.

Clinical Trial Conditions for Triamcinolone Acetate

Condition Name

Condition Name for Triamcinolone Acetate
Intervention	Trials
Glaucoma	3
Diabetic Macular Oedema	3
Macular Edema	2
Osteoarthritis (OA) of the Knee	1

Condition MeSH

Condition MeSH for Triamcinolone Acetate
Intervention	Trials
Macular Edema	7
Edema	5
Glaucoma	3
Retinal Vein Occlusion	2

Clinical Trial Locations for Triamcinolone Acetate

Trials by Country

Trials by Country for Triamcinolone Acetate
Location	Trials
United States	28
Brazil	4
Australia	3
Spain	3
Egypt	2

Trials by US State

Trials by US State for Triamcinolone Acetate
Location	Trials
California	7
Florida	3
Maryland	2
Pennsylvania	2
Illinois	2

Clinical Trial Progress for Triamcinolone Acetate

Clinical Trial Phase

Clinical Trial Phase for Triamcinolone Acetate
Clinical Trial Phase	Trials
PHASE4	1
PHASE1	1
Phase 4	8

Clinical Trial Status

Clinical Trial Status for Triamcinolone Acetate
Clinical Trial Phase	Trials
Completed	11
Recruiting	6
Unknown status	4

Clinical Trial Sponsors for Triamcinolone Acetate

Sponsor Name

Sponsor Name for Triamcinolone Acetate
Sponsor	Trials
University of Sydney	3
Palo Alto Medical Foundation	2
Assiut University	2

Sponsor Type

Sponsor Type for Triamcinolone Acetate
Sponsor	Trials
Other	33
Industry	7
U.S. Fed	1

Triamcinolone Acetate Market Analysis and Financial Projection

Last updated: February 9, 2026

Clinical Trials Update for Triamcinolone Acetate

Triamcinolone Acetate, a synthetic corticosteroid, is under ongoing clinical evaluation primarily for indications such as allergic conditions, dermatology, and inflammatory diseases. Recent updates indicate the following:

• Approved Indications: Widely approved for intra-articular injections, dermatological applications, and ocular inflammation.
• New Trials: Several phase II and III trials are evaluating its efficacy for conditions like vasculitis, asthma management, and nasal polyps.
• Regulatory Status: No recent filings for new indications or significant label extensions in the U.S., Europe, or Asia.
• Trial Completion Dates: Most active trials are expected to conclude between 2023 and 2025, with preliminary results indicating comparable efficacy to other corticosteroids but with a favorable safety profile.

Market Analysis

Current Market Landscape

Triamcinolone Acetate market value is driven by its widespread use in dermatology, orthopedics, and ophthalmology. The global corticosteroids market was valued at approximately $17.2 billion in 2022 and is projected to grow at a CAGR of 4.1% through 2028 [1].

• Key Regions: North America and Europe dominate the market, accounting for over 60% combined. Asia-Pacific shows significant growth potential due to rising healthcare infrastructure.
• Leading Companies: Pfizer, Sandoz (Novartis), and Mylan produce formulations of Triamcinolone Acetate.
• Pricing Dynamics: Generic versions have lowered prices, boosting accessibility and volume sales.

Competitive Landscape

Company	Product Name	Formulation	Approvals
Pfizer	Kenalog	Injectable, topical	U.S., EU, Japan
Sandoz (Novartis)	Triamcinolone Acetonide	Injectable, topical	Multiple markets
Mylan	Triamcinolone Acetonide	Topical, injectable	U.S., Europe

Market Drivers and Challenges

Drivers:

• Increasing prevalence of allergic and inflammatory disorders.
• Adoption of corticosteroids in combination therapy.
• Growth in minimally invasive procedures requiring corticosteroid injections.

Challenges:

• Competition from newer biologics and targeted therapies.
• Potential side effects, including adrenal suppression and osteoporosis.
• Regulatory scrutiny regarding systemic corticosteroid use.

Market Projection

Forecasting indicates that the global Triamcinolone Acetate market will reach approximately $3.2 billion by 2030, with a CAGR of 3.8% over the next eight years [2].

Key Factors Influencing Growth

• Expansion in Emerging Markets: Increasing healthcare access and awareness.
• New Indication Approvals: Regulatory approvals for additional uses, such as nasal sprays or inhalers, could expand market potential.
• Technological Innovations: Sustained-release formulations may improve patient compliance and treatment outcomes.

Potential Market Segments

1. Injectable formulations: Expected to lead with a substantial share due to use in joint injections and intraocular injections.
2. Topical formulations: Driven by dermatological applications.
3. Nasal and inhalation forms: Anticipated to grow as new delivery systems gain approval.

Conclusions

Triamcinolone Acetate remains a significant corticosteroid with steady demand driven by its broad therapeutic applications. Its clinical pipeline indicates potential for expanded indications, although competition from newer therapies and generics remains a factor. Market projections suggest moderate growth, primarily fueled by emerging markets and technological innovation.

Key Takeaways

• Current clinical trials focus on expanding indications, with results expected over the next two years.
• The global market is valued around $3.2 billion by 2030, growing at nearly 4% annually.
• Market growth hinges on regulatory approvals, innovation in delivery systems, and emerging-market penetration.
• Competition from biologics and side effect concerns limit further market expansion.
• The drug's versatile formulation portfolio supports ongoing demand in multiple therapeutic areas.

FAQs

1. Are there any new formulations of Triamcinolone Acetate under development?
Yes, sustained-release injectable and nasal spray formulations are in clinical development stages, aiming to improve compliance and broaden indicated uses.

2. What are the primary side effects associated with Triamcinolone Acetate?
Common side effects include skin thinning, joint pain, and systemic effects like adrenal suppression, especially with prolonged use.

3. How does Triamcinolone Acetate compare to other corticosteroids?
It offers similar efficacy but is often preferred for intra-articular and dermatological uses due to its potency and formulation options.

4. What is the outlook for Triamcinolone Acetate in emerging markets?
The market is poised for growth owing to increased healthcare access, though regulatory pathways and pricing remain considerations.

5. Will upcoming clinical trial results significantly impact the market?
Potentially. Successful trials demonstrating effectiveness for new indications could create new revenue streams, but competition and safety profiles will influence adoption.

---

References

[1] MarketsandMarkets, “Corticosteroids Market by Type,” 2022.
[2] Grand View Research, “Global Corticosteroids Market Size, Share & Trends,” 2022.